Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primary metabolites

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    374 result(s) found for: Primary metabolites. Displaying page 6 of 19.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-000995-24 Sponsor Protocol Number: GWEP1332 Start Date*: 2014-09-09
    Sponsor Name:GW Research Ltd
    Full Title: A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young ...
    Medical condition: Dravet Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-007705-37 Sponsor Protocol Number: C-08-36 Start Date*: 2009-08-13
    Sponsor Name:Alcon Research, Ltd
    Full Title: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    Medical condition: Geographic atrophy secondary to AMD
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001502-18 Sponsor Protocol Number: I3YMCJPBM Start Date*: 2014-11-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women ...
    Medical condition: Hormone Receptor Positive, HER2 negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in This Disease Setting
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) ES (Ongoing) IT (Completed) SK (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004567-21 Sponsor Protocol Number: 3119001 Start Date*: 2015-06-05
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension
    Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-006029-94 Sponsor Protocol Number: E5555-G000-201 Start Date*: 2008-01-23
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011078 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) BE (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-004397-27 Sponsor Protocol Number: 310741 Start Date*: 2007-10-19
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to or...
    Medical condition: Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to or...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040477 Sexual dysfunction LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005292-15 Sponsor Protocol Number: H7T-MC-TABR & TABR (1) Start Date*: 2006-03-02
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis
    Medical condition: Stable atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001559-11 Sponsor Protocol Number: 1312 Start Date*: 2013-09-13
    Sponsor Name:Herlev University Hospital
    Full Title: Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment.
    Medical condition: patients with cholangiocarcinoma after progression. When patients with cholangiocarcinoma cannot be operated, we cannot cure them. The purpose of oncologic treatment is to prolong survival and to e...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001386-81 Sponsor Protocol Number: 2016-1-DSF-MBC Start Date*: 2019-01-11
    Sponsor Name:Univerzita Palackého v Olomouci
    Full Title: PHASE II OPEN LABELED TRIAL OF DISULFIRAM WITH COPPER IN METASTATIC BREAST CANCERS.
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004583-22 Sponsor Protocol Number: IDRLS Start Date*: 2021-06-13
    Sponsor Name:Medical University of Innsbruck
    Full Title: Prospective analysis of the therapeutic efficacy of iron isomaltoside in combination with or without dopaminergic therapy in patients with restless legs syndrome
    Medical condition: Restless leg syndorme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001429-26 Sponsor Protocol Number: ZP1848-17127 Start Date*: 2019-05-08
    Sponsor Name:Zealand Pharma A/S
    Full Title: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
    Medical condition: Short bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) DK (Completed) PL (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002885-30 Sponsor Protocol Number: ARES Start Date*: 2017-07-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Novel strategies of antithrombotic prophylaxis in patients with Essential Thrombocythemia (ET) at high risk of cardiovascular events: comparison of different dosing regimens of administration of l...
    Medical condition: Essential thrombocytemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002989-12 Sponsor Protocol Number: IMR-BTL-201 Start Date*: 2020-06-02
    Sponsor Name:IMARA, Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
    Medical condition: β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000986-17 Sponsor Protocol Number: ALZ-801-201ADBM Start Date*: 2020-09-11
    Sponsor Name:Alzheon Inc.
    Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)
    Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004269-15 Sponsor Protocol Number: D-13-01 Start Date*: 2014-03-17
    Sponsor Name:Insituto Aragonés de Ciencias de la Salud
    Full Title: Aspirin and colorectal cancer prevention. Exploring the platelet hypothesis of its mechanism of action
    Medical condition: We will perform this clinical study to address the hypothesis that low-dose aspirin given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004854-46 Sponsor Protocol Number: 1333 Start Date*: 2014-04-04
    Sponsor Name:Herlev University Hospital
    Full Title: Randomized 1. Line treatment with gemcitabine, capecitabine, oxaliplatin vs gemcitabin and cisplatin to patients with cholangiocarcinoma.
    Medical condition: patient with metastatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003272-38 Sponsor Protocol Number: TPU-S1204 Start Date*: Information not available in EudraCT
    Sponsor Name:Taiho Pharma USA, Inc
    Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, TWO-STAGE, PHASE 2 STUDY OF S-1 IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER.
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001971-61 Sponsor Protocol Number: SALYCENDO Start Date*: 2016-08-29
    Sponsor Name:Radboudumc
    Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia.
    Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002941-23 Sponsor Protocol Number: GWEP1423 Start Date*: 2015-09-30
    Sponsor Name:GW Research Ltd.
    Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syn...
    Medical condition: Lennox-Gastaut syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003945-40 Sponsor Protocol Number: EPU-P112 Start Date*: 2019-04-10
    Sponsor Name:Maastricht University
    Full Title: EFFECTS OF VAPORISED CANNABIS, WITH AND WITHOUT CBD, ON DRIVING AND COGNITION
    Medical condition: This study will look at the differential effects of variations in cannabis chemovars on driving ability and cognition
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:21:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA